![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » MEDIMMUNE, INC. BREAKS GROUND ON NEW BIOLOGICS MANUFACTURING FACILITY IN FREDERICK, MARYLAND, A $250-MILLION EXPANSION
MEDIMMUNE, INC. BREAKS GROUND ON NEW BIOLOGICS MANUFACTURING FACILITY IN FREDERICK, MARYLAND, A $250-MILLION EXPANSION
MedImmune, Inc. announced its official groundbreaking to expand the biologics manufacturing facility at its existing site in Frederick, Maryland. MedImmune's Synagis (palivizumab), the first monoclonal antibody approved by the U.S. Food
and Drug Administration (FDA) to help prevent an infectious disease, is currently
produced at the site. The $250-million expansion is the first phase of a multi-phase
construction project that MedImmune announced last fall.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct